Teva: A Complete Overview

Teva down 60% YTD, what happened?

In Teva's (NYSE:TEVA) latest earnings report, the company reported a goodwill impairment charge of $6.1B, as widely reported by financial news outlets. Other financial metrics including sales growth continued their solid trend after the company's integration of its acquired Actavis. Sales of its Copaxone drug were down 10.3%, however, and sales are expected to continue that trend.


It's on us. Share your news here.

Submit your stories and articles to citybizlist today.